Embryonal tumors with MYCN deregulation such as neuroblastoma, retinoblastoma, medulloblastoma, Wilms tumor, and rhabdomyosarcoma are highly malignant and are often less amenable to targeted therapies. This evidence concerns the gene MYCN and Nephroblastoma.